2020 Drug Safety Communications

• FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid 10/15/2020
• FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl) 9/24/2020
• FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class 9/23/2020
• FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) 8/26/2020
• FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder  7/23/2020
• FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems 4/24/2020
• FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis 3/4/2020
• FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market 2/13/2020
• FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems 1/28/2020
• Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin) 1/14/2020